Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells

Fig. 4

ALK is detected in melanoma samples. (a) Immunohistochemistry and corresponding Hematoxylin and Eosin staining of FFPE slides of melanoma patient samples. ALK immunohistochemistry reveals a minor population of moderate immunopositive cells scattered throughout the tumour (Patients 1–4). Patient 5 is representative for ALK-negative sample. Magnification: 40X. (b) Table summarizing patient information. (c) Combination treatments with BRAF and ALK inhibitors strongly reduce melanoma tumour volumes. NSG mice were injected subcutaneously with 2 million A375-X1 cells. After 10 days, treatment was initiated by daily gavage (arrow). Tumour growth was followed over time (left panel) and weight of extracted tumours were measured (right panel). Data are presented as means of tumour volumes (mm3) ± SEM and means of tumour weights (mg) ± SEM, *p < 0.05, **p < 0.01, compared to vehicle-treated tumours (left panel); ***p < 0.001 between groups as indicated (right panel)

Back to article page